Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genelux Corporation - Common Stock (NQ:GNLX)

2.040 -0.030 (-1.45%)
Delayed Quote Updated: 10:13 AM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Genelux Corporation - Common Stock

< Previous 1 2 Next >
News headline image
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Participate in Upcoming Conferences
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Announces Proposed Public Offering of Common Stock
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Genelux Corporation
Via GlobeNewswire
News headline image
CurrencyNewsBreaks – Titan Partners Group LLC Acts as Sole Bookrunner for $10.5M Underwritten Offering
Via Investor Brand Network
Topics Economy
News headline image
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Announces New Chief Financial Officer
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
From Genelux Corporation
Via GlobeNewswire
News headline image
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
From Genelux Corporation
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.